Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estimulación del nervio vago para la artritis reumatoide de moderada a grave (RESET-RA)

13 de noviembre de 2026 actualizado por: SetPoint Medical Corporation

Estimulación del nervio vago con el sistema SetPoint para la artritis reumatoide de moderada a grave: el estudio RESET-RA

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter pivotal study enrolling up to 250 subjects at up to 45 study centers across the U.S. The study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA) who have had an inadequate response, loss of response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). The implant delivers a small amount of electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under general anesthesia. Half of the subjects will receive active stimulation (the treatment group) and the other half will receive non-active stimulation (the control group). Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety. Blinding will be maintained until the last enrolled and randomized subject in Stage 2 completes Week 12 assessments, and the study database is locked.

Tipo de estudio

Intervencionista

Inscripción (Actual)

243

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arizona
      • Mesa, Arizona, Estados Unidos, 85210
        • Arizona Arthritis ans Rheumatology Research, PPLC
      • Phoenix, Arizona, Estados Unidos, 85037
        • Arizona Arthritis Rheumatology & Research, PLLC
      • Tucson, Arizona, Estados Unidos, 85704
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Covina, California, Estados Unidos, 91722
        • Medvin Clinical Research
      • Upland, California, Estados Unidos, 91786
        • Inland Rheumatology Clinical Trials
      • Whittier, California, Estados Unidos, 90602
        • Medvin Clinical Research
    • Colorado
      • Fort Collins, Colorado, Estados Unidos, 80528
        • The Arthritis & Rheumatology Clinic of Northern Colorado
    • Connecticut
      • Stamford, Connecticut, Estados Unidos, 06905
        • Stamford Therapeutics Consortium
    • Delaware
      • Lewes, Delaware, Estados Unidos, 19958
        • Delaware Arthritis
    • Florida
      • Aventura, Florida, Estados Unidos, 33180
        • Arthritis & Rheumatic Disease Specialties
      • Avon Park, Florida, Estados Unidos, 33825
        • HARAC Research Corporation
      • Boynton Beach, Florida, Estados Unidos, 33472
        • RecioMed Clinical Research Network, Inc.
      • Clearwater, Florida, Estados Unidos, 33765
        • Bay Area Rheumatology
      • Plantation, Florida, Estados Unidos, 33324
        • IRIS Research and Development
    • Georgia
      • Augusta, Georgia, Estados Unidos, 30912
        • Augusta University
      • Lawrenceville, Georgia, Estados Unidos, 30044
        • Parris and Associates Rheumatology
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Northwestern University
      • Willowbrook, Illinois, Estados Unidos, 60527
        • Willow Rheumatology and Wellness PLLC
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology
    • Michigan
      • Lansing, Michigan, Estados Unidos, 48910
        • June DO, PC
    • Minnesota
      • Eagan, Minnesota, Estados Unidos, 55121
        • Saint Paul Rheumatology, P.A.
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64151
        • Kansas City Physician Partners
      • St Louis, Missouri, Estados Unidos, 63122
        • West County Rheumatology
    • Nebraska
      • Lincoln, Nebraska, Estados Unidos, 68516
        • Physician Research Collaboration, LLC
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87102
        • Albuquerque Center for Rheumatology
    • New York
      • Babylon, New York, Estados Unidos, 11702
        • Long Island Regional Arthritis & Osteoporosis Care
    • North Carolina
      • Charleston, North Carolina, Estados Unidos, 28202
        • Arthritis & Osteoporosis Consultants Of The Carolinas
      • Charlotte, North Carolina, Estados Unidos, 28210
        • DJL Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73103
        • Health Research of Oklahoma, PLLC
      • Oklahoma City, Oklahoma, Estados Unidos, 73116
        • Rheumatology Associates of Oklahoma
    • Pennsylvania
      • Allentown, Pennsylvania, Estados Unidos, 18103
        • Lehigh Valley Health Network
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania Medical Center
    • Texas
      • Allen, Texas, Estados Unidos, 75013
        • Arthritis & Rheumatology Research Institute, PLLC
      • Austin, Texas, Estados Unidos, 78745
        • Tekton Research
      • Austin, Texas, Estados Unidos, 78717
        • Austin Regional Clinic
      • Austin, Texas, Estados Unidos, 78746
        • Central Texas Rheumatology Associates
      • Colleyville, Texas, Estados Unidos, 76034
        • Precision Comprehensive Clinical Research Solutions
      • Houston, Texas, Estados Unidos, 77043
        • Biopharma Informatic
      • Mesquite, Texas, Estados Unidos, 75150
        • Southwest Rheumatology Research LLC
      • San Antonio, Texas, Estados Unidos, 78229
        • Clinical Trials of Texas, Inc
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22033
        • Annapolis Rheumatology
    • Washington
      • Bothell, Washington, Estados Unidos, 98021
        • Sound Clinical Research, LLC
    • West Virginia
      • Morgantown, West Virginia, Estados Unidos, 26506
        • West Virginia University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

22 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • 22-75 years of age at screening
  • Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
  • Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
  • Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12

Exclusion Criteria:

  • Untreated or poorly controlled psychiatric illness or history of substance abuse
  • Significant immunodeficiency due to underlying illness
  • History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
  • Clinically significant cardiovascular disease
  • Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
  • Uncontrolled fibromyalgia
  • History of left or right carotid surgery
  • History of unilateral or bilateral vagotomy, partial or complete splenectomy
  • Recurrent vasovagal syncope episodes
  • Current, regular use of tobacco products
  • Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Treatment

Active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Otros nombres:
  • Colocación quirúrgica del estimulador del nervio vago dentro del cuello

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Otros nombres:
  • Tratamiento de base con FARME sintético convencional

Active stimulation for 1 min once per day

Comparador falso: Control

Non-active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Otros nombres:
  • Colocación quirúrgica del estimulador del nervio vago dentro del cuello

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Otros nombres:
  • Tratamiento de base con FARME sintético convencional

Non-active stimulation for 1 min once per day

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
the American College of Rheumatology (ACR) 20 Response
Periodo de tiempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
DAS28-CRP Good or Moderate Response as Defined by European League Against Rheumatism (EULAR)
Periodo de tiempo: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

A subject is considered having a moderate treatment response if:

  • DAS28-CRP score improvement from baseline to Week 12 is > 0.6 and ≤ 1.2, and the DAS28-CRP score at Week 12 is ≤ 5.1; or
  • DAS28-CRP score improvement from baseline to Week 12 is > 1.2, and the DAS28-CRP score at Week 12 is > 3.2.

A subject is considered having a good treatment response if:

• DAS28-CRP score improvement from baseline to Week 12 is > 1.2 and the DAS28-CRP score at Week 12 is ≤ 3.2

Week 12
DAS28-CRP Response (MCID -1.2) at Week 12
Periodo de tiempo: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) response is based on the minimal clinically important difference (MCID) of -1.2 from baseline.

DAS28-CRP is based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

Week 12
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22)
Periodo de tiempo: Week 12

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 12
ACR20 Response at Week 12 From Day 0
Periodo de tiempo: Week 12

Response is defined as achieving at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL).

Week 12

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Bone Erosion Progression, All Completers
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers With Erosive Phenotype
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers That Previously Only Failed 1 b/tsDMARD
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Change in Erosion Score, All Completers
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers With Erosive Phenotype
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers That Previously Only Failed 1 b/tsDMARD
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Synovitis Score, All Completers
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers With Erosive Phenotype
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Osteitis Score, All Completers
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers With Erosive Phenotype
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Periodo de tiempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission
Periodo de tiempo: Week 12

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 12
DAS28-CRP Low Disease Activity (LDA) or Remission
Periodo de tiempo: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 12
the American College of Rheumatology (ACR) 20 Response, All Completers
Periodo de tiempo: Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Periodo de tiempo: Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Periodo de tiempo: Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Periodo de tiempo: Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Study Participants That Are Somewhat to Very Satisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Periodo de tiempo: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Neither Satisfied Nor Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Periodo de tiempo: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Somewhat to Very Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Periodo de tiempo: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Would Recommend the SetPoint System to a Family Member or Friend
Periodo de tiempo: Week 24

Patients were asked a question about whether they would recommend the SetPoint System to family and friends

Week 24
the American College of Rheumatology (ACR) 20 Response, All Completers
Periodo de tiempo: Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Periodo de tiempo: Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Periodo de tiempo: Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Periodo de tiempo: Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
the American College of Rheumatology (ACR) 20 Response, All Completers
Periodo de tiempo: Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Periodo de tiempo: Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Periodo de tiempo: Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Periodo de tiempo: Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
the American College of Rheumatology (ACR) 20 Response, Subjects With 1 Prior b/tsDMARD
Periodo de tiempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 2 Prior b/tsDMARD
Periodo de tiempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 3 Prior b/tsDMARD
Periodo de tiempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With >=4 Prior b/tsDMARD
Periodo de tiempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Mark Richardson, MD PhD, Massachusetts General Hospital
  • Investigador principal: John Tesser, MD, Arizona Arthritis and Rheumatology Research, P.C.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

11 de enero de 2021

Finalización primaria (Actual)

16 de mayo de 2024

Finalización del estudio (Estimado)

1 de octubre de 2027

Fechas de registro del estudio

Enviado por primera vez

31 de agosto de 2020

Primero enviado que cumplió con los criterios de control de calidad

31 de agosto de 2020

Publicado por primera vez (Actual)

7 de septiembre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de enero de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • SPM-020

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

No sharing data is planned.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .